Dear Sir, It was of interest to read the case report on musical obsessions (Journal 1999, 41,77-78) . The clinical picture, especially the phenomenon of a particular set of known musical notes repeatedly being perceived resembles Palinacousis. This phenomenon was descnbed by Jacob and associates in 1973 as persistent or recurring paroxysmal auditory illusions in which enviornmentally produced auditory perceptions persist or recur for a vanable length of time after the initial stimulus has ended. These palinacoustic events are exact replicas or fragments of the original sound. The source may be a voice, music or random noises and the sensation is often indistinguishable from the original stimulus. They are generally neutral in content and characteristically occur in the absence of other psychiatric symptoms (Malone & Leiman, 1983) . Palinacousis is considered as a manifestation of temporal lobe dysfunction and responds to anticonvulsant medication (Patterson & Tomlinson, 1988) Awareness of this interesting phenomenon of Palinacousis is useful when evaluating symptoms of the nature described in the case report. 
RISPERIDONE IN SCHIZOPHRENIA

Sir,
Risperidone is a newer antipsychotic with broad spectrum of antipsychotic efficacy and with significantly less extrapyramidal side'effects. There are plenty of studies reported from western countries regarding its efficacy in schizophrenia (Mattes, 1997). Till date there are only two clinical trials reported from India in schizophrenia (Agarwal et al ,1998; Agashe et al.,1999) . The last article was published in Indian Journal of Psychiatry. 1999,41(1), 54-59. This study reports significant improvement of both positive and negative symptoms with better extrapyramidal side effect profiie Since the authors have selected both DSM-III-R defined schizophrenia patients with duration of illness more than 6 months and schizophreniform patients with duration of illness less than 6 month it is premature to conclude risperidone's antipsychotic efficacy. As this trial has continued upto 4 months many of the cases of schizophreniform psychoses would have spontaneously remitted. Further discrepancy noted in the result is the mention of minimum duration of schizophrenic illness as 1 year which is contradictory to the inclusion of schizophreniform illness. It would have been more meaningful if the author's have separately analysed the clinical response of schizophrenic and schizophreniform patients. A comparative analysis of improvement in positive symptoms versus negative symptoms may shed more light on the differential response of risperidone which is not yet studied. Another discrepancy notice in the article was the conclusion of significantly less extrapyramidal side effects though table 3 of adverse effects gives 40% prevalence when clubbing, tremor, rigidity, sialorrhoea, oculogyric crisis and akatrtisia. From table 2, it is clear that extrapyramidal side effects were already present in many patients before starting risperidone. Hence it is difficult to say that side affects are due to risperidone as many of these patients were already receiving oral/parenteral neuroleptic at the time of intake into the trial. Three days stoppage of antipsychotic is not enough in the assessment of side effect profile especially with depot preparation whose side effects can last even for months.
We conducted an open clinical trial of risperidone (6-8 mg/day) on a group of DSM-IV defined 24 drug naive schizophernic population
